Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments. This is a video synopsis/summary of an Insights ...

To better understand the experience of those living with eye mites, we spoke to one optometrist and two people who have had ...

Dr Shamie shares her optimism in the advancement of Demodex Blepharitis treatment. This is a video synopsis/summary of an Insights involving Neda Shamie, MD. With an FDA-approved treatment now ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...

Please provide your email address to receive an email when new articles are posted on . Demodex blepharitis is so common that it makes up more than two thirds of all blepharitis cases. In fact, nearly ...

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle. Xdemvy ™ (lotilaner ophthalmic solution) is now available for the ...

Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan ...